NCT01087411

Brief Summary

The purpose of this study is to study whether a targeted intervention can increase physical activity in inactive 8-yr old children and how it affects secondary measures such as metabolic- and cardiovascular risk factors and markers, self-reported quality of life, BMI, body composition and aerobic work-capacity.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2008

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

March 15, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 16, 2010

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

February 24, 2021

Status Verified

February 1, 2021

Enrollment Period

3.7 years

First QC Date

March 15, 2010

Last Update Submit

February 22, 2021

Conditions

Keywords

accelerometryphysical activityobesitychildrencardiovascular risk markersmetabolic risk markersDXAobesity preventionomega 3fish liver oilmotivational interviewing

Outcome Measures

Primary Outcomes (1)

  • Change in level of physical activity

    Physical activity, is measured with tri-axis accelerometers of the brand Actigraph model GT3X. Data is collected every 10 seconds during 7 consecutive whole days. It is the most feasible and precise method for the purpose.

    screening, 0 and 15 weeks and 12 months

Secondary Outcomes (7)

  • Body composition

    0 and 15 weeks

  • Cardiovascular risk markers

    0 and 15 seeks

  • BMI (Body Mass Index)

    0 and 15 weeks

  • Quality of life scale

    0 and 15 weeks

  • Self reported motor skills

    0 and 15 weeks

  • +2 more secondary outcomes

Study Arms (4)

Motivational Interviewing and omega 3

EXPERIMENTAL

This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.

Behavioral: Motivational InterviewingBehavioral: Physical activityDietary Supplement: Supplementation with fish liver oli capsules

Motivational interviewing and placebo

EXPERIMENTAL

This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.

Behavioral: Motivational InterviewingBehavioral: Physical activityDietary Supplement: Placebo oil capsules

Control and omega 3

EXPERIMENTAL

This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.

Dietary Supplement: Supplementation with fish liver oli capsules

Control and placebo

PLACEBO COMPARATOR

This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.

Dietary Supplement: Placebo oil capsules

Interventions

The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.

Motivational Interviewing and omega 3Motivational interviewing and placebo

Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.

Motivational Interviewing and omega 3Motivational interviewing and placebo

This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.

Control and omega 3Motivational Interviewing and omega 3
Placebo oil capsulesDIETARY_SUPPLEMENT

This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.

Control and placeboMotivational interviewing and placebo

Eligibility Criteria

Age7 Years - 9 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Level of physical activity below the 30ieth percentile cut off point derived from a large reference population.

You may not qualify if:

  • Family not being able to participate in the program or take part in at least the physical activity assessment.
  • Morbidities that affects the outcome parameters.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Division of Pediatrics.

Huddinge, Södermanland County, 14186, Sweden

Location

MeSH Terms

Conditions

Sedentary BehaviorOverweightMotor ActivityObesity

Interventions

Motivational InterviewingExerciseDietary Supplements

Condition Hierarchy (Ancestors)

BehaviorOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Directive CounselingCounselingMental Health ServicesBehavioral Disciplines and ActivitiesHealth ServicesHealth Care Facilities Workforce and ServicesMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Pernilla Danielsson Liljeqvist, MD

    Karolinska Institutet

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 15, 2010

First Posted

March 16, 2010

Study Start

October 1, 2008

Primary Completion

June 1, 2012

Study Completion

December 1, 2012

Last Updated

February 24, 2021

Record last verified: 2021-02

Locations